Fadi Taza, MD

[OncUpdates @OncUpdates]

⭐️@ASCO #GU26: Exciting shifts in #BladderCancer!

🔥Expert panelists @reichard_chad @shilpaonc @siadaneshmand and Dr. Galsky join the @OncBrothers to breakdown the latest study updates!

#OncTwitter #Oncology #FOAMed #MedEd #MedTwitter

Full discussion👇
https://t.co/UyRrH7PYOQ

[Fadi Taza, MD @FadiTaza]

@JenniferKingMD 👏🏻👏🏻

[Matt Campbell MD, MS @DocMattCampbell]

Congratulations to the Indiana team with @JenniferKingMD and @nabiladra presenting cabozantinib in refractory GCT, CBR 43%, very tough area to make progress, glad to see multiple MOAs advancing to try and bring better options for this patient population

[Nabil Adra @nabiladra]

@IUCancerCenter @IUuro

[Nabil Adra @nabiladra]

@JenniferKingMD @IUCancerCenter @IUSMDeptMed

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

Our outstanding fellows @JenniferKingMD @faditaza and Meagan Miller presented their #ASCO2022 abstracts at IUSCC Grand Rounds 👏🏻👏🏻👏🏻 @IUCancerCenter @IUSMDeptMed

[Fadi Taza, MD @FadiTaza]

Had a great time at #ASCO2022

[Nabil Adra @nabiladra]

IU super fellow Fadi Taza presenting results for Indiana Univ experience with high dose chemo in relapsed non-seminoma @IUSMDeptMed @IUCancerCenter @IUHemOnc @faditaza

[Indiana University Hematology/Oncology Fellowship @IUHemOnc]

Outstanding weekend at ASCO! Please stop by our fellow's posters today. @ASCO @IUCancerCenter @IUMedSchool #ASCO2022

@faditaza #216
@ArdeshirFatemeh #217
@JenniferKingMD #218

[Fadi Taza, MD @FadiTaza]

@Hemoncq https://t.co/yoUxqaUbV2

[Fadi Taza, MD @FadiTaza]

@ACCinTouch @ArjunKanwalMD @SrihariNaiduMD Proud of you, Arjun!

[Fadi Taza, MD @FadiTaza]

@NazliDizman @NatureMedicine @montypal @LuisMezaco @PauloBergerot @crisbergerot @urotoday @ASCO @DrChoueiri @neerajaiims @PGrivasMDPhD @DrRaviSalgia @TDorffOnc @KidneyCancer @kidneycan Congratulations!! Great work!

[Journal of Clinical Oncology @JCO_ASCO]

.@EAntonarakis & @faditaza et al. demonstrate from 123 pts w/ mCRPC having BRC1/2 alterations that PARP inhib activity is decreased in BRCA1 vs. BRCA2 and could likely be influenced by more monoallelic mut or concurrent TP53 mut in BRCA1 group https://t.co/p4Yfp9HwL4 #JCOPO #pcsm

[Fadi Taza, MD @FadiTaza]

We hope that additional studies will lead to more treatment options for BRCA1-altered mCRPC.

I am so grateful for the opportunity to work with @nabiladra @albanymd @heatherhcheng @sokolova_md @neerajaiims @AlanBryce9 @PBarataMD @jberchuck @cnsternberg @Panos_Vlach @CathyHandy

[Fadi Taza, MD @FadiTaza]

1/8
“But is it one for all, or all for one?” @EAntonarakis once said.

Excited to share our work "PARPi efficacy in BRCA1/BRCA2 altered mCRPC patients".

Incredibly thankful to @EAntonarakis !!!

Check the #tweetorial 👇
@asco @OncoAlert @IUCancerCenter
https://t.co/NzYl0Z1V4o

[Fadi Taza, MD @FadiTaza]

8/8
In summary:
PARP inhibitor activity is attenuated in mCRPC patients with BRCA1 mutations.

The diminished efficacy appears to be associated with a greater number of monoallelic (rather than biallelic) mutations and a higher prevalence of concurrent TP53 alterations in BRCA1.